Comparing SpringWorks Therapeutics (NASDAQ:SWTX) & Genenta Science (NASDAQ:GNTA)

SpringWorks Therapeutics (NASDAQ:SWTX) and Genenta Science (NASDAQ:GNTA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares SpringWorks Therapeutics and Genenta Science’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SpringWorks Therapeutics	-115.60%	-51.10%	-43.80%
Genenta Science	N/A	N/A	N/A

Institutional & Insider Ownership

15.1% of Genenta Science shares are held by institutional investors. 7.8% of SpringWorks Therapeutics shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares SpringWorks Therapeutics and Genenta Science”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SpringWorks Therapeutics	$191.59 million	18.43	-$258.13 million	($3.41)	-13.74
Genenta Science	N/A	N/A	-$9.64 million	N/A	N/A

Genenta Science has lower revenue, but higher earnings than SpringWorks Therapeutics.

Volatility & Risk

SpringWorks Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for SpringWorks Therapeutics and Genenta Science, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SpringWorks Therapeutics	0	7	1	0	2.13
Genenta Science	0	0	1	0	3.00

SpringWorks Therapeutics presently has a consensus target price of $52.57, suggesting a potential upside of 12.19%. Genenta Science has a consensus target price of $25.00, suggesting a potential upside of 664.53%. Given Genenta Science’s stronger consensus rating and higher probable upside, analysts plainly believe Genenta Science is more favorable than SpringWorks Therapeutics.

Summary

Genenta Science beats SpringWorks Therapeutics on 9 of the 10 factors compared between the two stocks.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.